SCHEMBL14770529

SCHEMBL14770529

CC(c1ccc(OCc2cc(F)ccc2F)cc1)c1nc2cc(C(F)(F)F)ccc2[nH]1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.38
IDO1 P14902 4/20 0.38
SCN10A Q9Y5Y9 1/20 0.36
CACNA1C Q13936 1/20 0.36
PRCP P42785 2/20 0.33
CYP1A1 P04798 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP1B1 Q16678 1/20 0.33
HTR2A P28223 2/20 0.33
HTR2C P28335 2/20 0.33
SLC6A4 P31645 2/20 0.33
PDE2A O00408 3/20 0.32
ESR1 P03372 1/20 0.32
NR3C1 P04150 1/20 0.32
PGR P06401 1/20 0.32
NR3C2 P08235 1/20 0.32
AR P10275 1/20 0.32
ESR2 Q92731 1/20 0.32
MAOB P27338 1/20 0.32
LMNA P02545 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14770531 0.91 CACNA1C (0.40) CACNA1CCYP1A1CYP1A2CYP1B1HTR2A
SCHEMBL14770530 0.87 CACNA1C (0.38) CACNA1CCYP1A1CYP1A2CYP1B1HTR2A
SCHEMBL14770537 0.87 CACNA1C (0.38) FFAR1CACNA1CCYP1A1CYP1A2CYP1B1
SCHEMBL14770532 0.87 AMY1A (0.38) CACNA1CCYP1A1CYP1A2CYP1B1MAOB
SCHEMBL14770527 0.87 CACNA1C (0.38) IDO1CACNA1CCYP1A1CYP1A2CYP1B1
SCHEMBL12066062 0.87 FFAR1 (0.44) FFAR1IDO1SCN10ACACNA1CPRCP
SCHEMBL14770526 0.87 CACNA1C (0.48) CACNA1CCYP1A1CYP1A2CYP1B1HTR2A
SCHEMBL14770538 0.86 CACNA1C (0.40) IDO1CACNA1CPRCPCYP1A1CYP1A2
SCHEMBL14770528 0.85 NPC1 (0.42) CACNA1CCYP1A1CYP1A2CYP1B1LMNA
SCHEMBL14762921 0.84 FFAR1 (0.39) FFAR1IDO1CACNA1CCYP1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A FFAR1 1112/4885IDO1 1108/4885SCN10A 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.